Barclays analyst Matt Miksic raised the firm’s price target on Orchestra BioMed (OBIO) to $12 from $11 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO: